作者: Olimpiadi, Yuliya ; Kamalanathan, Kaylee J. ; Hong, Jiarong ; Schaap, Grant ; Bae, Song Yi ; Galeano-Garces, Catalina ; Hesch, Alexa ; Mallery, Kevin ; Drake, Justin ; Travadi, Yash ; Parthasarathy, Jayant ; Pederson, Sarah ; Bristow, Nathaniel R. ; Horrmann, Alec ; Konety, Badrinath R.

AbstractThe 5-year breast cancer survival rate in the United States is 91% overall with a 99% survival rate for localized disease. Early detection via mammograms has largely been responsible for the success of finding breast cancer early; however, mammograms have drastically decreased effectiveness in women with dense breasts tissue which is approximately half of the US population. To better serve these women, an alternative screening method is necessary. Astrin Biosciences has developed a multi-modal liquid biopsy-based alternative for breast cancer screening in this population.Recent literature demonstrates that cancer cells disseminate into blood vessels even at early stages. These early-stage cells are a potential source of late recurrence and therapy resistance but have strong potential benefit in early detection as well as provide opportunities to determine possibly curative interventions. Although these cell assays have a huge potential benefit, they generally leave some to be desired as far as sensitivity due to the rarity of these cells with less than 10 cells per 10 mL blood tube from circulation. To overcome this limitation, Astin’s algorithm pairs our AI-empowered proprietary holographic imaging platform with plasma proteomics. This pairing provides increased sensitivity over a cell-based assay alone while maintaining the ability to detect disseminating cells for further analysis in patients with enough cells present.This combined technology was evaluated in a cohort of more than 100 newly diagnosed early-stage breast cancer patients (Stage 0, 1, and 2). Blood samples were collected prior to initiation of therapy and the plasma and cell fractions were separated. Proteomic analysis was performed on the plasma sample while Astrin’s holographic imaging platform combined with in-flow protein marker expression was used to analyze the samples for circulating tumor cells. Preliminary data from this study demonstrates evidence of early dissemination detectable in the majority of breast cancer patients. GSEA analysis of protein expression revealed well known pathways associated with cancer biology. Astrin Biosciences’ combined assay has the ability to detect cancer in women with dense breast, increasing the likelihood cancer is detected early in this population.Citation Format:Kaylee J. Kamalanathan, Alec Horrmann, Nathaniel R. Bristow, Yash Travadi, Kevin Mallery, Catalina Galeano-Garces, Song Yi Bae, Alexa Hesch, Grant Schaap, Yuliya Olimpiadi, Sarah Pederson, Jiarong Hong, Justin Drake, Jayant Parthasarathy, Badrinath R. Konety. Multi-modal liquid biopsy analysis of early-stage breast cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1026.

项与 Astrin Biosciences Inc 相关的新闻（医药）

2024-01-24

·PRNewswire

Astrin Biosciences and Leading New York Cancer Center Announce New Cancer Research Collaboration

NEW YORK, Jan. 24, 2024 /PRNewswire/ -- In a significant advancement for cancer research and treatment, Astrin Biosciences, a leader in AI-empowered 3D holographic technology for cancer cell detection, has announced a comprehensive research collaboration with Memorial Sloan Kettering Cancer Center (MSK). This collaboration will leverage the combined strengths of both organizations, with the goal of transforming biomarker development and its role in cancer research and treatment. Continue Reading Cancer cell hologram The collaboration sets the stage for an integrated approach, enabling researchers from Astrin and MSK to work together on a wide range of projects across the spectrum of cancer care. The collaboration is fueled by a shared commitment to eradicate the global scourge of cancer. Astrin's Founder and CEO, Jayant Parthasarathy, PhD, expressed his gratitude and optimism, "We are deeply honored to collaborate with MSK. Their trust in our platform is a testament to our technology's potential. Together, we have a remarkable opportunity to make a significant impact on the lives of those affected by cancer." "This collaboration holds immense promise for advancing our understanding of cancer, from early detection to addressing the challenges of treatment resistance and disease complexity," said Howard I. Scher, MD, FASCO, Head of MSK's Biomarker Program and a world-renowned expert in cancer diagnostics. The collaboration promises to accelerate the development of innovative cancer diagnostics and treatments. It underscores the commitment of both Astrin Biosciences and MSK to lead the charge in the global fight against cancer. For more information about this collaboration, please contact: [email protected] About Astrin Biosciences Astrin Biosciences is at the forefront of cancer research, revolutionizing the field with its AI-empowered 3D holographic imaging technology for detecting cancer cells. The company is dedicated to harnessing the power of technology to accelerate early detection and advance cancer care (). SOURCE Astrin Biosciences

100 项与 Astrin Biosciences Inc 相关的药物交易

登录后查看更多信息

100 项与 Astrin Biosciences Inc 相关的转化医学

登录后查看更多信息